Related Experiment Video

Updated: Jun 6, 2026

A High Resolution Method to Monitor Phosphorylation-dependent Activation of IRF3
11:44

A High Resolution Method to Monitor Phosphorylation-dependent Activation of IRF3

Published on: January 24, 2016

A single nucleotide polymorphism in activated Cdc42 associated tyrosine kinase 1 influences the interferon therapy in

Yoshifumi Fujimoto1, Hidenori Ochi, Toshiro Maekawa

  • 1The Institute of Physical and Chemical Research, Katsumi, Minami-ku, Hiroshima, Japan.

Journal of Hepatology
|December 7, 2010
PubMed
Abstract

Insights

A specific gene variant (SNP rs2278034) in ACK1 is linked to interferon therapy success in hepatitis C virus (HCV) patients. This finding suggests ACK1 plays a role in the body's antiviral response to HCV.

Area of Science:

  • Genetics
  • Virology
  • Immunology

Background:

  • Hepatitis C virus (HCV) infection is a global health concern.
  • Cdc42, a Rho family GTPase, is implicated in HCV infectivity.
  • Interferon (IFN) therapy is a common treatment for HCV.

Purpose of the Study:

  • To investigate the association between Cdc42-related genes and the outcome of IFN therapy in HCV patients.
  • To explore the role of the activated Cdc42 associated tyrosine kinase 1 (ACK1) gene in HCV treatment response.

Main Methods:

  • Genotyping of 17 single nucleotide polymorphisms (SNPs) in CDC42 and ACK1 genes.
  • Analysis of IFN therapy outcomes (sustained responders vs. non-responders) in 409 HCV patients.
  • Replication study with 794 additional IFN-treated patients and in vitro experiments using Huh7 and HCV-N replicon cells.

Main Results:

  • SNP rs2278034 in the ACK1 gene was significantly associated with IFN therapy outcome (p=6.4 × 10(-4)).
  • Replication confirmed this association for IFN monotherapy but not for combination therapy.
  • ACK1 expression enhanced IFN-stimulated gene (ISG) transcription and promoter activity, and inhibited HCV replication in vitro.

Conclusions:

  • The SNP rs2278034 in ACK1 is a potential predictive marker for IFN therapy response in HCV patients.
  • ACK1 may contribute to innate and IFN-induced antiviral mechanisms against HCV.
  • Further research into ACK1's role could inform novel therapeutic strategies for HCV.

More Related Videos

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice09:03

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice

Published on: February 3, 2012

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...